Skip to Content
Merck
All Photos(1)

Key Documents

D5193

Sigma-Aldrich

17-Dimethylaminoethylamino-17-demethoxygeldanamycin

Synonym(s):

17-DMAG

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C32H48N4O8
Molecular Weight:
616.75
UNSPSC Code:
51102829
NACRES:
NA.85
Pricing and availability is not currently available.

biological source

synthetic

Quality Level

100

form

powder

color

dark red-purple to black

solubility

ethanol: ~10 mg/mL (lit.)
DMSO: >25 mg/mL (lit.)

antibiotic activity spectrum

neoplastics

Mode of action

protein synthesis | interferes

storage temp.

−20°C

General description

Chemical structure: benzenoid

Application

17-DMAG has been used to block the NF-κB inflammatory cascade in the murine model[1]. It a potential therapeutic agent for non-small-cell lung cancers (NSCLC)[2].

Biochem/physiol Actions

17-DMAG is a heat shock protein (HSP90) inhibitor. 17-DMAG is a more potent analog of geldanamycin. It inhibits cancer growth and promotes apoptosis in multiple cell lines. 17-DMAG is a more potent antitumor agent than 17-AAG.
17-DMAG is a more potent analog of geldanamycin. Inhibits cancer growth and promotes apoptosis in multiple cell lines. 17-DMAG is a more potent antitumor agent than 17-AAG.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCT9570
MKCQ1422
MKCP2844
MKCL9260
MKCK7397

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.
Shimp SK 3rd, Parson CD, et al.
Inflammation Research, epub (2012)
Naruyuki Kobayashi et al.
Lung cancer (Amsterdam, Netherlands), 75(2), 161-166 (2011-07-20)
Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after initiation of TKIs therapy. Non-small-cell lung cancers (NSCLC) with activating EGFR mutations were reported to be sensitive to heat shock protein 90 (Hsp90)

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service